Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Gary J. Kelloff"'
Autor:
Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava
Publikováno v:
Cancer Research. 83:1175-1182
Big data in healthcare can enable unprecedented understanding of diseases and their treatment, particularly in oncology. These data may include electronic health records, medical imaging, genomic sequencing, payor records, and data from pharmaceutica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71f4d3e129a9c64d20c7837ca7bd3bb5
https://doi.org/10.1158/0008-5472.can-22-1274
https://doi.org/10.1158/0008-5472.can-22-1274
Autor:
Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis D. Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo H. Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava
Publikováno v:
Cancer Research. 83:1183-1190
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9042c740550e4c3e4949faea3069c247
https://doi.org/10.1158/0008-5472.can-22-1277
https://doi.org/10.1158/0008-5472.can-22-1277
Autor:
Eva Szabo, Caroline C. Sigman, Samir N. Khleif, Gary J. Kelloff, Olivera Finn, Ronald B. Herberman, Gary Gordon, Dean E. Brenner, Gregory A. Curt, Frank L. Meyskens
This article endeavors to clarify the current requirements and status of regulatory approval for chemoprevention (risk reduction) drugs and discusses possible improvements to the regulatory pathway for chemoprevention. Covering a wide range of topics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fa3f75d71d704b4a7f8b8484b2f7389
https://doi.org/10.1158/1940-6207.c.6544541
https://doi.org/10.1158/1940-6207.c.6544541
Autor:
Eva Szabo, Caroline C. Sigman, Samir N. Khleif, Gary J. Kelloff, Olivera Finn, Ronald B. Herberman, Gary Gordon, Dean E. Brenner, Gregory A. Curt, Frank L. Meyskens
Supplementary Appendices from Regulatory Approval of Cancer Risk-Reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f211a2c1a237431095ca6307a8dddac
https://doi.org/10.1158/1940-6207.22525025
https://doi.org/10.1158/1940-6207.22525025
Autor:
Elena Zamagni, Nancy Valente, A. Kate Sasser, Michael D. Robbins, Gregory H. Reaman, Trevor J. Pugh, James L. Omel, Lata Mukundan, Jens G. Lohr, Robert D. Loberg, Richard F. Little, Ilan R. Kirsch, J. Milburn Jessup, Mohamad A. Hussein, Howard R. Higley, Steven I. Gutman, Jennifer S. Dickey, Alessandra Di Bacco, Faith E. Davies, Michele Cavo, Nikhil C. Munshi, Ola Landgren, Shaji K. Kumar, Nicole J. Gormley, Ann T. Farrell, Hervé Avet-Loiseau, Caroline C. Sigman, Gary J. Kelloff, Daniel Auclair, Kenneth C. Anderson
Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::072f8abff7a8382f994326641bd6b620
https://doi.org/10.1158/1078-0432.c.6527112.v1
https://doi.org/10.1158/1078-0432.c.6527112.v1
Autor:
Elena Zamagni, Nancy Valente, A. Kate Sasser, Michael D. Robbins, Gregory H. Reaman, Trevor J. Pugh, James L. Omel, Lata Mukundan, Jens G. Lohr, Robert D. Loberg, Richard F. Little, Ilan R. Kirsch, J. Milburn Jessup, Mohamad A. Hussein, Howard R. Higley, Steven I. Gutman, Jennifer S. Dickey, Alessandra Di Bacco, Faith E. Davies, Michele Cavo, Nikhil C. Munshi, Ola Landgren, Shaji K. Kumar, Nicole J. Gormley, Ann T. Farrell, Hervé Avet-Loiseau, Caroline C. Sigman, Gary J. Kelloff, Daniel Auclair, Kenneth C. Anderson
1) Munshi Figures, 2) MRD Negativity Associated With Longer Progression-free Survival And Overall Survival In Newly Diagnosed Multiple Myeloma Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee7ddae316376c1796d95cc311ead6a1
https://doi.org/10.1158/1078-0432.22468986
https://doi.org/10.1158/1078-0432.22468986
Autor:
Elena Zamagni, Nancy Valente, A. Kate Sasser, Michael D. Robbins, Gregory H. Reaman, Trevor J. Pugh, James L. Omel, Lata Mukundan, Jens G. Lohr, Robert D. Loberg, Richard F. Little, Ilan R. Kirsch, J. Milburn Jessup, Mohamad A. Hussein, Howard R. Higley, Steven I. Gutman, Jennifer S. Dickey, Alessandra Di Bacco, Faith E. Davies, Michele Cavo, Nikhil C. Munshi, Ola Landgren, Shaji K. Kumar, Nicole J. Gormley, Ann T. Farrell, Hervé Avet-Loiseau, Caroline C. Sigman, Gary J. Kelloff, Daniel Auclair, Kenneth C. Anderson
Active Clinical Trials in Myeloma Using Minimal Residual Disease Assessment as Exploratory or Secondary Endpoints
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::087d270bf48117bb98f21a77b05d054d
https://doi.org/10.1158/1078-0432.22468980.v1
https://doi.org/10.1158/1078-0432.22468980.v1
Autor:
Robert T. McCormack, Daniel Stetson, Dana E. Connors, J. Carl Barrett, Kenneth D. Cole, Steven P. Lund, Chris Karlovich, Thomas Forbes, P. Mickey Williams, Megan H. Cleveland, Laura M. Yee, Christie J. Lau, Cloud P. Paweletz, Gary J. Kelloff, Benoit Destenaves, Hua-Jun He, Susan M. Keating
Publikováno v:
JCO Precision Oncology
PURPOSEWe report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65932e30bc1310e4e98453053f022f10
https://doi.org/10.1200/po.20.00528
https://doi.org/10.1200/po.20.00528
Autor:
Kenneth C. Anderson, Daniel Auclair, Stacey J. Adam, Amit Agarwal, Melissa Anderson, Hervé Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E. Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M. Ghobrial, Nicole J. Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J. Kelloff, Ilan R. Kirsch, Brandon Kremer, Ola Landgren, Elizabeth Lightbody, Oliver C. Lomas, Sagar Lonial, María-Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C. Munshi, Elizabeth K. O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J. Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A. Ross, Caroline C. Sigman, Katie L. Thoren, Suzanne Trudel, Gary Ulaner, Nancy Valente, Brendan M. Weiss, Elena Zamagni, Shaji K. Kumar
Publikováno v:
Clinical Cancer Research. 27:5195-5212
The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5e26c526f80115989596e628f2bce9a
https://doi.org/10.1158/1078-0432.ccr-21-1059
https://doi.org/10.1158/1078-0432.ccr-21-1059
Autor:
J. Carl Barrett, Preeti Narayan, Soma Ghosh, Laurel J. Pracht, Gary J. Kelloff, Julia A. Beaver, Geoffrey R. Oxnard, Reena Philip, P. Mickey Williams, Justin I. Odegaard, Robert T. McCormack
Publikováno v:
Oncologist
With advances in precision oncology, liquid biopsies have shown promise as a minimally invasive means to diagnose cancer and guide treatment decisions. This commentary presents an assessment of the potential and the challenges of widespread use of li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37d7142197cda6b122bdc06ae1b5eada
https://doi.org/10.1634/theoncologist.2020-0246
https://doi.org/10.1634/theoncologist.2020-0246